Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Non-cash Items: 2021-2024

Historic Non-cash Items for SAB Biotherapeutics (SABS) over the last 4 years, with Dec 2024 value amounting to $6.3 million.

  • SAB Biotherapeutics' Non-cash Items rose 71.01% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 71.01%. This contributed to the annual value of $6.3 million for FY2024, which is 847.42% up from last year.
  • According to the latest figures from FY2024, SAB Biotherapeutics' Non-cash Items is $6.3 million, which was up 847.42% from $664,967 recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Non-cash Items registered a high of $28.9 million during FY2021, and its lowest value of $109,891 during FY2022.
  • Its 3-year average for Non-cash Items is $2.4 million, with a median of $664,967 in 2023.
  • As far as peak fluctuations go, SAB Biotherapeutics' Non-cash Items crashed by 99.62% in 2022, and later surged by 847.42% in 2024.
  • Yearly analysis of 4 years shows SAB Biotherapeutics' Non-cash Items stood at $28.9 million in 2021, then plummeted by 99.62% to $109,891 in 2022, then skyrocketed by 505.12% to $664,967 in 2023, then soared by 847.42% to $6.3 million in 2024.